Latest
Congress Presses FDA to Do More to Combat Drug Shortages
Legislators have requested that FDA do more to prevent drug shortages.
Pharm Exec's Top 50 Companies 2018
Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth.
China's Removal of Imported Drug Tariffs: Implications for Foreign and Domestic Companies
On May 1, China eliminated the tariff on 28 categories of imported drugs. Jin Zhang looks at the implications for foreign and domestic pharma companies.
C-Suite Personality: Fit for Future?
Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.
Pharm Exec Video
The Fundamental Disconnect Between Pharma and Technology
Otsuka Pharmaceuticals' William Carson explains the growing pains the company and its technology partner went through in reaching FDA approval for their digital medicine system.
Pharma’s Data Tsunami Problem
William Carson, Otsuka Pharmaceuticals' president & CEO of development and commercialization, talks about the industry's challenges in tackling the huge amounts of collected data.
Healthcare Robotics: Meet Mabu Your Personal Health Companion
Take a sneak peek at what the future of home healthcare could look like with the use of robotics and artificial intelligence.
New & Noteworthy
Can Trump Plan Serve as Model for What Ails Europe?
Weighing the crossover effect of US’s new pricing blueprint.
Leveraging Lab Data in Advent of Personalized Marketing
Laboratory testing has become a critical access point for sales teams in the age of personalized medicine, writes Melissa Leonhauser.
US Maps Strategy to Reform Drug Pricing
Azar and Gottlieb out front in revising rebates, restructuring Medicare, and promoting competition. Jill Wechsler reports.
Brands of the Year: Promise and Challenge
In its 12th annual feature, Pharm Exec profiles a new round of biopharma products that are making waves in five key areas in healthcare and R&D.
Sales & Marketing
Leveraging Lab Data in Advent of Personalized Marketing
Laboratory testing has become a critical access point for sales teams in the age of personalized medicine, writes Melissa Leonhauser.
Building a Key Account Organization: 5 Power Questions
If companies are serious about building a sustainable organization for their employees and becoming a partner to key accounts, they need to be prepared to remodel their whole business around it, writes Miranda Wheatley Price.
Why "Episodes" Matter for Doctors
A customer "episode" is a key unit of management that can produce significant growth and cost savings, write Rafael Natanek and George Eliades.
eBooks
Emerging BioPharma: Your Guide to Clinical and Commercial Considerations
This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways.
PEspeaks
Deciphering the EU Health Policy Hieroglyphs
Figuring out the workings of the EU in topics related to health can be akin to deciphering Egyptian hieroglyphs, making it challenging for companies to plan ahead, writes Reflector.
How to Run Your Biotech Like the Kraft Family Runs the New England Patriots
Jonathan Kraft shares his family's secrets on what it takes to lead a successful organization, while also creating lasting brand power.
What Can Pharmaceutical Companies do to Feel Better About Reputation?
Reputation Institute study finds that the reputation of pharma companies is in decline and might get worse before it gets better.
Insights for the Win
Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.
Piecing Together the Pricing Puzzle: The Midterm Elections
There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.
Emerging Pharma Leaders
Interviews
Amryt Pharma: Realizing Rare Disease Treatments
Pharm Exec speaks with Joe Wiley, CEO of Amryt Pharma, who is steering a road-less-traveled path for a small pharma—building a sustainable, commercial infrastructure first, with the hopes of accelerating new rare disease drugs to the market.
Digital Health: Regulatory, Compliance, and Legal Challenges
Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.
Analytics, AI, and the Internet of Things in the Real World
IBM Watson Health's Peter Brandsetter talks about how analytics, IoT, and AI are moving from buzzwords to real-world solutions with benefits that weren't possible just a few years ago.
Regulatory
Congress Presses FDA to Do More to Combat Drug Shortages
Legislators have requested that FDA do more to prevent drug shortages.
Digital Health: Regulatory, Compliance, and Legal Challenges
Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.
Piecing Together the Pricing Puzzle: The Midterm Elections
There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.
From the Editor
Insights for the Win
Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.
So Much Depends on the Physician
Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.
|
|---|
|
Sponsored Links
Global
China's Removal of Imported Drug Tariffs: Implications for Foreign and Domestic Companies
On May 1, China eliminated the tariff on 28 categories of imported drugs. Jin Zhang looks at the implications for foreign and domestic pharma companies.
Deciphering the EU Health Policy Hieroglyphs
Figuring out the workings of the EU in topics related to health can be akin to deciphering Egyptian hieroglyphs, making it challenging for companies to plan ahead, writes Reflector.
Can Trump Plan Serve as Model for What Ails Europe?
Weighing the crossover effect of US’s new pricing blueprint.
The PD-1/PD-L1 Race in China
The PD-1/PD-L1 market in China is heating up and companies there have made a series of advances, writes Jin Zhang.
Gauging the Collaborative Spirit in European Health
Pair of EU meetings, while well-meant, offered little action and beg the question—what’s the true merit in working together?
Strategy
Building a Key Account Organization: 5 Power Questions
If companies are serious about building a sustainable organization for their employees and becoming a partner to key accounts, they need to be prepared to remodel their whole business around it, writes Miranda Wheatley Price.
Engaging with Stakeholders In the Information Age
With so much information readily available companies have lost a significant level of control over how and when details about their progress in drug development and planning related to approval, launch, and commercialization are disseminated.
Patient Advocacy: an Overlooked Strategy for Achieving Equitable Market Success?
Ellen Coleman outlines the highlights of a recent webinar on ensuring that patient advocacy is a key element of a market access strategy.
Technology
Digital Health: Regulatory, Compliance, and Legal Challenges
Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.
Analytics, AI, and the Internet of Things in the Real World
IBM Watson Health's Peter Brandsetter talks about how analytics, IoT, and AI are moving from buzzwords to real-world solutions with benefits that weren't possible just a few years ago.
Asembia 2018: User-Friendly Urgency
Michelle Maskaly reports on the possibilities for high tech and the patient journey in specialty pharma, as discussed at the recent Asembia conference in Las Vegas.
